Cellectis to Present Data at the 2018 ASGCT Annual Meeting

May 10, 2018 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that three posters regarding the Company's allogeneic off-the-shelf CAR-T product candidates and one poster associated with the Company’s technology will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held from May 16 to 19, 2018, in Chicago, Illinois.

 

• Universal CAR T-Cells Targeting CS1 (UCARTCS1) for the Treatment of Multiple Myeloma

 

Agnès Gouble¹, Roman Galetto¹, Rohit Mathur³, Stephanie Filipe¹, Isabelle Chion-Sotinel¹, Jing Yang³, Jin He³, Robert Z. Orlowski³, Sattva S. Neelapu³ and Julianne Smith²

¹Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France

²Cellectis, Inc., 430 East 29th Street, 10016 New York, NY

³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030

 

Poster number: 130

Cancer - Targeted Gene & Cell Therapy I

Wednesday, May 16, 2018 at 5:30 PM - Stevens Salon C, D

 

• Repurposing endogenous immune pathways to improve chimeric antigen receptor T-cells potency

 

M. Sachdeva¹, B. Busser¹, S. Temburni¹, A. Juillerat¹, L. Poirot², P. Duchateau², J. Valton¹;

¹Cellectis, Inc., New York, NY

²Cellectis, Paris, France

 

Poster number: 774

Cell Therapies III

Friday, May 18, 2018 at 5:45 PM - Stevens Salon C, D

 

• Engineering CAR T-Cells with an Integrated off Switch to Enhance Safety Performance

 

Alexandre Juillerat¹, Diane Tkach¹, Brian W. Busser¹, Sonal Temburni¹, Julien Valton¹, Aymeric Duclert², Laurent Poirot² and Philippe Duchateau²

¹Cellectis, Inc., 430E, 29th Street, NYC, NY 10016

²Cellectis SA, 8 rue de la Croix Jarry, 75013 Paris, France

 

Poster number: 739

Cancer - Immunotherapy, Cancer Vaccines III

Friday, May 18, 2018 at 5:45 PM - Stevens Salon C, D

 

Presented by Allogene Therapeutics, Inc.:

 

• Cynomolgus macaque gene-edited CAR T-cell platform: towards a reliable in vivo allogeneic model to assess safety and Efficacy

 

Diego A. Vargas-Inchaustegui¹, Rory Dai¹, Alexandre Juillerat², Christopher Do¹, Kris Poulsen¹, Thomas Pertel¹, Barbra Sasu¹

¹Allogene Therapeutics, Inc., South San Francisco, CA,

²Cellectis, Inc., New York, NY

 

Poster number: 131

Cancer - Targeted Gene & Cell Therapy I

Wednesday, May 16, 2018 at 5:30 PM - Stevens Salon C, D

 

 

Abstracts are available on the ASGCT website. The 4 posters to be presented at the 2018 ASGCT Annual Meeting will be available on the Cellectis website after May 19, 2018.